Demographic and Clinical Characteristics of Chronic BZD Users at the Start of PDSI Phase 2
| Characteristica | No. (%) (N = 24,512) |
|---|---|
| Age, y | |
| 75-79 | 9,385 (38.3) |
| 80-84 | 8,438 (34.4) |
| 85-89 | 4,463 (18.2) |
| ≥90 | 2,226 (9.1) |
| Male | 23,952 (97.7) |
| Race | |
| White | 22,939 (93.6) |
| Black | 1,008 (4.1) |
| Other | 452 (1.8) |
| Missing | 113 (0.5) |
| Rurality | |
| Urban | 14,881 (60.7) |
| Rural | 9,188 (37.5) |
| Highly rural | 413 (1.7) |
| Missing | 30 (0.1) |
| Depression | 2,317 (9.5) |
| Anxiety | 8,946 (36.5) |
| PTSD | 2,875 (11.7) |
| Alcohol-related disorder | 541 (2.2) |
| Non-alcohol substance-related disorder | 239 (1.0) |
| Dementia | 1,296 (5.3) |
| Insomnia | 4,666 (19.0) |
| Chronic pain | 15,470 (63.1) |
BZD = benzodiazepine; PDSI = Psychotropic Drug Safety Initiative; PTSD = posttraumatic stress disorder; VA = Veterans Affairs.
↵a Race, rurality, and clinical conditions derived per Stroupe et al,16 the VA Information Resource Center,17 and Maust et al,5 respectively.